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Blood serum of patients with diabetic
kidney disease stimulates thrombospondin 1
gene expression in peripheral blood
mononuclear cells
Surowica krwi od pacjentów z cukrzycową chorobą nerek wzmacnia ekspresję
genu dla trombospondyny 1 w komórkach jednojądrzastych krwi obwodowej
ABSTRACT
Background. The thrombospondin 1 and cyclooxy-
genase 1 genes were over-expressed and the matrix
metalloproteinase 9 and cyclooxygenase 2 genes
have lower expression in peripheral blood mononuc-
lear cells (PBMC) of type 1 diabetic patients with dia-
betic kidney disease (DKD). The aim of the study was
to examine if the expression of those genes could
be stimulate by incubating PBMC of healthy volun-
teers in blood serum of patients with DKD.
Material and methods. Blood serum samples from
five type 2 diabetic patients with DKD and five type
2 diabetic patients without DKD were collected.
PBMC of four healthy volunteers were incubated in
blood serum of 5 type 2 diabetic patients with DKD
and 5 without DKD. The expression of the thrombo-
spondin 1, cyclooxygenase 1, matrix metalloprotei-
nase 9 and cyclooxygenase 2 genes was examined
using a method based on the real-time PCR. The
expression was compared between cells incubated
in blood serum of type 2 diabetic patients with and
without DKD.
Results. We observed a higher expression of the
thrombospondin 1 gene in cells incubated in blood
serum of patients with DKD. The expression of other
genes did not differ between cells incubated in blood
serum of patients with and without DKD.
Conclusions. Blood serum of type 2 diabetic patients
with DKD induces expression of thrombospondin 1
gene in PBMC. Blood serum of type 2 diabetes
patients with DKD may contain an intrinsic factor
which may be involved in vascular complications
accelerated by DKD. (Diabet. Klin. 2012; 1, 2: 55–60)
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STRESZCZENIE
Wstęp. Wykazano, że komórki jednojądrzaste krwi
obwodowej u chorych na cukrzycę typu 1 z cukrzy-
cową chorobą nerek charakteryzują się zwiększoną
ekspresją genów dla trombospondyny 1 i cyklooksy-
genazy 1 oraz zmniejszoną ekspresją genów dla meta-
loproteinazy 9 i cyklooksygenazy 2. Celem badania było
sprawdzenie, czy ekspresja tych genów może zostać
zmieniona przez inkubację komórek jednojądrzastych
krwi obwodowej od zdrowych ochotników w surowi-
cy krwi chorych z cukrzycową chorobą nerek.
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Materiał i metody. Pobrano próbki surowicy krwi od
5 chorych na cukrzycę typu 2 z cukrzycową chorobą
nerek oraz 5 chorych na cukrzycę typu 2 bez cukrzy-
cowej choroby nerek. Komórki jednojądrzaste krwi
obwodowej od 4 zdrowych ochotników były inku-
bowane w surowicy krwi od 5 chorych na cukrzycę
typu 2 z cukrzycową chorobą nerek i 5 chorych bez
cukrzycowej choroby nerek. Zbadano ekspresję ge-
nów dla trombospondyny 1, cyklooksygenazy 1,
metaloproteinazy 9 i cyklooksygenazy 2, używając
metody opartej na reakcji łańcuchowej polimerazy
DNA z analizą ilości produktu w czasie rzeczywistym.
Porównano ekspresję genów pomiędzy komórkami
inkubowanymi w surowicy krwi od chorych na cu-
krzycę typu 2 z i bez cukrzycowej choroby nerek.
Wyniki. Stwierdzono większą ekspresję genu dla
trombospondyny 1 w komórkach inkubowanych
w surowicy chorych z cukrzycową chorobą nerek. Eks-
presja pozostałych genów nie różniła się między ko-
mórkami inkubowanymi w surowicy od chorych
z cukrzycową chorobą nerek i bez tej choroby.
Wnioski. Surowica krwi od chorych na cukrzycę typu
2 z cukrzycową chorobą nerek powoduje wzrost eks-
presji genu dla trombospondyny 1 w komórkach jed-
nojądrzastych krwi obwodowej. Surowica krwi od
chorych na cukrzycę typu 2 z cukrzycową chorobą
nerek może zawierać czynnik biorący udział w powi-
kłaniach naczyniowych, których postęp jest szybszy
przy obecności cukrzycowej choroby nerek.
(Diabet. Klin. 2012; 1, 2: 55–60)
Słowa kluczowe: cukrzycowa choroba nerek,
ekspresja genu, komórki jednojądrzaste krwi
Background
Diabetic kidney disease (DKD) is a frequent
cause of chronic kidney disease. The pathomecha-
nism of DKD is not well explained. Approximately
one third of patients with diabetes is predisposed
to DKD. Numerous studies have searched genetic
marker which predicts predisposition to DKD. No
marker useful for clinical practice has been found
yet. An alternative way to find a marker of genetic
predisposition to DKD may be an analysis of gene
expression. Different models of gene expression were
used to analyze gene expression in diabetic kidney
disease. The most popular model was based on cul-
tured skin fibroblasts of diabetes patients [1]. We
started a new model using peripheral blood mono-
nuclear cells (PBMC) of patients with DKD [2]. Using
this model we analyzed expression of over 20 tho-
usand genes in peripheral blood mononuclear cells
(PBMC) of patients with DKD [2]. Using the method
based on microarray we found that the thrombo-
spondin 1 (THBS1) and cyclooxygenase 1 (PTGS1)
genes were over-expressed and matrix metallopro-
teinase 9 (MMP9) and cyclooxygenase 2 (PTGS2)
genes had lower expression in PBMC of type 1 dia-
betic men with DKD [2]. The different expression of
those four genes might be primary marker of gene-
tic predisposition to DKD or secondary consequen-
ce of development of DKD.
To examine the hypothesis that different gene
expression might be secondary to development of
DKD we examined the effect of blood serum from
patients with DKD on gene expression in PBMC from
healthy volunteers. PBMC of healthy volunteers were
incubated in blood serum samples of type 2 diabe-
tes patients with DKD. Gene expression of the throm-
bospondin 1, cyclooxygenase 1, metalloproteinase 9
and cyclooxygenase 2 genes were examined and
compared to gene expression in PBMC incubated in
blood serum of type 2 diabetes patients without
DKD.
Material and methods
Blood serum sample collection
Venous blood (10 ml) was drawn from 10 type 2
diabetic patients into serum tube. 5 patients had
urine albumin excretion in the range of macroalbu-
minuria and 5 patients had normal urine albumin
excretion. Macroalbuminuria was defined as albumin
to creatinine ratio (ACR) ≥ 300 mg/g and normoal-
buminuria as ACR < 30 mg/g. Blood samples were
centrifuged at 2000 g for 10 min at room tempera-
ture (20°C) and blood serum was transfered to sepa-
rate tubes and frozen in –20°C. All enrolled patients
gave written informed consent for participation in
the study. The Ethics Committee of the Medical Uni-
versity of Lodz approved the study protocol.
Incubation of PBMC and RNA isolation
Venous blood was drawn from four healthy
volunteers (4 men in the age from 27 to 43 years)
into EDTA-coated tubes. The aliquots of each sam-
ple (2.7 ml) blood were carefully layered on the top
of 2.7 ml Gradisol L solution (Polfa, Kutno, Poland).
Samples were then centrifuged at 400 g for 30 min
at room temperature (20°C). The interphase (500 µl)
containing PBMC was then transferred to 1500 µl
of 1 × phosphate-buffered saline (PBS) and mixed
by inverting the tubes. The sample centrifuged
at 250 g for 10 min at room temperature. The su-
pernatant was discarded and the cell pellet was re-
suspended in 500 µl of blood serum from type 2
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diabetic patients and transferred to 2-ml tubes, and
the lids were tightly closed.
Peripheral blood mononuclear cells from each
healthy volunteers were incubated in 10 samples from
type 2 diabetic patients, 5 with and 5 without DKD.
Altogether 40 incubations experiments were perfor-
med (4 healthy volunteers × 10 blood serum sam-
ples of type 2 diabetic patients). The samples were
incubated for 2 h at 37°C and then centrifuged
at 10000 g for 30 s at room temperature. The super-
natant was discarded and the cell pellet was re-su-
spended in 500 µl of the TRIzol® Reagent (Invitro-
gen, Carlsbad, CA, USA). Total RNA was isolated using
the TRIZOL reagent according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA).
Reverse transcription and real-time PCR
Total RNA (1,0 µg) was reverse transcribed
using random decamers RETROscript™ First Strand
Synthesis Kit for RT-PCR (Ambion, Austin, USA). Re-
agents were incubated for 60 min at 42°C followed
by 10 min at 92°C. KAPA SYBR® FAST qPCR Master
Mix (2×) Bio-Rad iCyclerTM Kit (Kapa Biosystems Inc.,
Boston, MA, USA) was used on the Bio-Rad iQTM5
Real Time PCR System (Bio-Rad Laboratories, Hercu-
les, CA, USA) to amplify human cDNAs as well as
the cDNA for GAPDH gene as the internal control.
PCR reactions were carried out in a total volume of
25 µl containing 7.5 µl of cDNA with the following
thermocycling steps: 95°C for 20 s, then 40 cycles
of 95°C for 3 s, and 60°C for 30 s, followed by mel-
ting curve data collection.
In the real-time PCR experiment, the data analy-
sis and calculations were performed using the 2–DDCT
method described previously [3]. Expression was as-
sessed by analyzing threshold cycle (CT) values. The
relative amount of expressed mRNA was calculated
by comparison with the expression of the houseke-
eping GAPDH gene amplified in a separate tube.
Using the 2–DDCT method, the data are presen-
ted as the fold change in gene expression normali-
zed to an endogenous reference gene (GAPDH) and
relative to the expression in cells incubated in blood
serum of patients without DKD.
All primers used for real-time semiquantitati-
ve PCR were described previously [4–7]. Primers used
for semiquantitative real-time PCR were purchased
from MolBiol (Poznan, Poland).
The following primers were used for GAPDH,
thrombospondin 1 (THBS1), cyclooxygenase 1 (PTGS1),
cyclooxygenase 2 (PTGS2) and matrix metalloprote-
inase 9 (MMP9), respectively, in real-time PCR:
— GAPDH antisense, 5'-CGCCCAATACGACCAAAT-3';
— GAPDH sense, 5'-AGTCAGCCGCATCTTCTT-3' [4];
— THBS1 antisense, 5'-CTGATCTGGGTTGTGGTTGTA-3';
— THBS1 sense, 5'-CCTGTGATGATGACGATGA-3' [4];
— PTGS1 sense 5'-GCTATTCCGGCCCCAACT-3';
— PTGS1 antisense 5'-GATGAAGGTGGCATTGACA-
AACT-3' [5];
— PTGS2 sense 5'-CTTTGCCCAGCACTTCA-3';
— PTGS2 antisense 5'-CTAGCCAGAGTTTCACCGTAA-
3' [6];
— MMP9 sense 5'-CGGCTTGCCCTGGTGCAGT-3';
— MMP9 antisense 5'-CGTCCTGGGTGTA-
GAGTCTCTCG-3' [7].
The results for the THBS1 gene expression were
confirmed in the repeated real-time PCR assay. For fi-
nal analysis of the THBS1 gene expression mean va-
lues of both assays were used.
Statistical analysis
Statistical analysis was performed using so-
ftware R version 2.11.1 (The R Foundation for Stati-
stical Computing). Analysis of variance was used to
compare the gene expression in PBMC after incuba-
tion in blood serum of type 2 diabetes patients. Gene
expression was a dependent variable, and the ori-
gin of PBMC from healthy volunteers and the pre-
sence of DKD in blood serum donor were the inde-
pendent variables in the model.
Results
Clinical characteristics of type 2 diabetes pa-
tients was presented in table 1. Five patients had
DKD with urine albumin excretion in the range of
macroalbuminuria. Five patients with normal urine
albumin excretion.
Peripheral blood mononuclear cells of four he-
althy volunteers were incubated 2 hours in blood
serum samples from 5 type 2 diabetic patients with
DKD and from 5 type 2 diabetic patients with nor-
mal urine albumin excretion. The expression of the
THBS1, PTGS1, PTGS2 and MMP9 genes in the PBMC
incubated in blood serum of patients with DKD was
compared to gene expression of PBMC incubated in
blood serum of patients without DKD (table 2).
The expression of the THBS1 gene was higher in
PBMC incubated in blood serum of patients with
DKD. Figure 1 presents the boxplot of the THBS1
gene expression depending on the origin of blood
serum. There was no difference in the expression of
the PTGS1, PTGS2 and MMP9 genes between PBMC
incubated in blood serum of type 2 diabetic patients
with and without DKD (tab. 2).
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Discussion
We found that blood serum of patients with
DKD induced the THBS1 gene expression in PBMC
of healthy volunteers. We had found previously that
the THBS1 gene expression was higher in type 1 dia-
betic men with DKD than in type 1 diabetic men
without DKD. Those observations indicate that an
increased expression of the THBS1 gene is seconda-
ry to development of DKD. It may suggest presence
of an intrinsic factor in blood serum of patients with
DKD, which stimulates expression of the THBS1 gene
in PBMC.
Table 1. Clinical characteristics of type 2 diabetic donors of blood sera. Data are presented as median (minimum–
–maximum)
Patients  with DKD Patients  without DKD
n 5 5
Age (years) 66 (54–75) 64 (45–71)
Duration of diabetes after diagnosis (years) 10 (5–19) 16 (10–17)*
HbA1c (%) 7.2 (6.1–7.6) 10.6 (8.0–12.5)*
BMI [kg/m2] 31.6 (30.4–32.6) 29.3 (22.5–32.4)
Serum creatinine concentration [µmol/L] 207 (134–220) 82 (72–110)*
GFR MDRD [ml/min/1,73 m2] 23 (20–36) 71 (61–110)*
C-reactive protein [mg/l] 4.4 (2.1–13) 4.9 (2.4–13.1)
Retinopathy (yes/no) 5/0 2/3
History of myocardial infarction, CABG, PTCA or stroke (yes/no) 1/4 0/5
*p < 0.05
Table 2. Gene expression in PBMC of healthy volunteers
incubated with blood serum of five type 2 diabetic pa-
tients with DKD compared to cells incubated in blood
serum of five type 2 diabetic patients without DKD
Gene name Change in gene P
expression
Thrombospondin 1 (THBS1) 2.06 0.033
Cyclooxygenase 1 (PTGS1) 0.76 0.311
Cyclooxygenase 2 (PTGS2) 0.63 0.120
Matrix metalloproteinase 9 (MMP9) 0.93 0.808
Figure 1. Boxplot of the expression of the THBS1 gene de-
pending on the presence of DKD in blood serum donor.
The data are presented as 100 × THBS1/GAPDH expression.
DKD — incubation in blood serum of type 2 diabetic pa-
tient with DKD; no-DKD — incubation in blood serum of
type 2 diabetic patient without DKD
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The increased expression of the THBS1 gene
may be induced by renal damage in the course of
DKD. The effect of kidney diseases on other organs
was described in epidemiological studies [8-10]. In-
creased urine albumin excretion and impaired renal
function accelerated atherosclerosis [8, 9] and in-
duced progression of diabetic retinopathy [10]. In
the presented study all patients with diabetic kid-
ney disease had retinopathy, however the presence
of retinopathy was one of the inclusion criteria in
the DKD group to avoid non-diabetic kidney dise-
ase. An increased expression of the THBS1 gene mi-
ght be associated with arterial diseases accelerated
by DKD. A linear correlation between peripheral ar-
terial disease and thrombospondin 1 plasma level
was observed [11]. Thrombospondin 1 was impli-
cated in profibrotic, proinflamatory, antiangiogenic
and proapoptotic effects [12]. Thrombospondin 1
expression was increased in glumeruli from the ear-
liest stage of DKD [13]. Thrombospondin 1 was an
endogenous activator of TGF-b in experimental DKD
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[14]. Its expression was also increased in kidney
during hypoxia [15].
Thrombospondin 1 is expressed by a variety
of cell types such as platelets, vascular smooth mu-
scle cells as well as diverse renal cells including me-
sangial cells, podocytes, endothelial cells, tubular
and interstitial cells [12]. Thrombospondin 1 is re-
gulated by various cytokines such as platelet deri-
ved growth factor, fibroblast growth factor 2 or
transforming growth factor beta, and is frequently
expressed at sites of inflammation, wound healing
and tissue remodeling [12, 16]. Thrombospondin
1 might be a target in prevention and treatment of
DKD what has been already shown in animal model
[17, 18]. Proteinuria was significantly improved in
mice treated with LSKL peptide [18]. LSKL is a pepti-
de which inhibits thrombospondin 1 activation of
TGF-ß. LSKL treatment reduced urinary TGF-b activity
and improved markers of tubulointerstitial injury [18].
A similar model was used by other research
group, which investigated an exposure of normal
human podocytes to the sera of diabetic patients
with albuminuria [19]. They observed cytoskeleton
remodeling, cellular insulin resistance and suscepti-
bility to apoptosis in cells exposed to sera of diabe-
tic patients with DKD. They found significant mo-
dulation of several genes involved in cytokines
action, actin remodeling and insulin signaling [19].
Presence of a circulating factor responsible for po-
docyte malfunction was suggested in patients with
albuminuria [19]. The factor that might stimulates
thrombospondin 1 gene expression in PBMC expo-
sed to blood serum of patients with DKD is not
known. In the recent study C-reactive protein (CRP)
induced thrombospondin 1 protein release and
mRNA expression from human renal tubular epithe-
lial cells incubated with purified CRP via activation
of the p38MAPK and NF-kB signaling pathways [20].
CRP might be one of the circulating factors indu-
cing thrombospondin-1 gene expression. However,
in our study no correlation was found between
thrombospondin 1 gene expression and CRP con-
centration in blood serum donors.
Cells isolation and material preparation might
have an influence on gene expression per se. To avoid
that potential effect we coded and mixed the sam-
ples of patients with and without DKD during all
steps of material preparation.
Patients without DKD had longer duration of
diabetes after diagnosis than patients with DKD.
They may be protected against DKD by some gene-
tic background, what might have an impact on the
observed results.
In summary, blood serum of type 2 diabetic
patients with DKD increased the expression
of thrombospondin 1 gene in peripheral blood mo-
nonuclear cells of healthy volunteers. Blood serum
of type 2 diabetes patients with DKD may contain
an intrinsic factor which may be involved in vascular
complications accelerated by DKD.
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